Lupus & antiphospholipid syndrome
Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE
Authors' conclusion
Patients with SLE have lower antibody levels following 2 doses of COVID-19 vaccines compared to HC. In SLE lower lymphocyte counts and serum IgA levels are associated with lower antibody levels post vaccination, potentially identifying a subgroup of patients who may therefore be at increased risk of infection.
Study context
- Population
- Patients with SLE and matched healthcare worker healthy controls, 4–8 weeks after second COVID-19 vaccine dose (BNT162b2 or ChAdOx1 nCoV-19)
- Participants
- 43 vs 40
- Exposure
- SLE vs matched healthcare worker healthy controls
- SLEn = 43
- Healthy controls (HC)n = 40reference
- Outcome
- Anti-SARS-CoV-2 spike glycoprotein antibody levels (IgGAM ELISA)
- Follow-up
- 4-8 weeks following the second COVID-19 vaccine dose
Methodological detailsmatched by age, sex and ethnic background
- Matched by age, sex and ethnic background
Main finding
As reported in the abstract
- Antibody levels were lower in SLE patients compared to HC
- SLE vs HC: P < 0.001
Observational data: associations, not effects.
Further findings
Higher serum IgA and higher anti-SARS-CoV-2 antibody tertile (SLE)
| OR (95% CI) | P value | ||
|---|---|---|---|
| Higher serum IgANot IgG or IgM | 1.820 (1.050–3.156) | P = 0.033 | |
| 0.20.5125Odds ratio (log scale) |
Higher lymphocyte count and higher anti-SARS-CoV-2 antibody tertile (SLE)
| OR (CI) | P value | ||
|---|---|---|---|
| Higher lymphocyte count | 3.330 (1.505–7.366) | P = 0.003 | |
| 0.10.31310Odds ratio (log scale) |
Association of antibody levels with medication, lupus disease activity, vaccine type or prior COVID infection (SLE)
- No association
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →